Furthermore, we used pharmacological blockers (SH045 and BI-749327) in vivo and ex vivo to verify findings from the genetical model and to evaluate effects of TRPC6 inhibition in IRI-induced AKI and intrarenal regulation of blood flow. The gene discussed is TRPC6; the disease is acute kidney injury.